Roth Capital Comments on Journey Medical FY2025 Earnings

Key Points

• Analysts at Roth Capital have decreased their FY2025 earnings per share forecast for Journey Medical from ($0.23) to ($0.32).
• Journey Medical's stock has experienced a slight decline, trading down 0.8% to $7.20, as analysts have provided mixed ratings, with some downgrading their outlook.
• The company reported a quarterly earnings miss, with an EPS of ($0.16), falling short of the consensus estimate of ($0.07).

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Roth Capital reduced their FY2025 earnings per share (EPS) estimates for Journey Medical in a note issued to investors on Tuesday, August 12th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.32) per share for the year, down from their prior forecast of ($0.23). The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share.

Other analysts have also issued research reports about the company. Alliance Global Partners reaffirmed a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th. Lake Street Capital upped their price objective on Journey Medical from $9.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Wall Street Zen lowered Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Finally, Zacks Research lowered Journey Medical from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Journey Medical currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.83.

Journey Medical Price Performance

NASDAQ DERM remained flat at $7.07 on Friday. The company's stock had a trading volume of 102,342 shares, compared to its average volume of 109,648. The company has a market capitalization of $164.73 million, a price-to-earnings ratio of -18.61 and a beta of 0.80. The company has a quick ratio of 0.95, a current ratio of 1.27 and a debt-to-equity ratio of 1.11. Journey Medical has a 52 week low of $3.54 and a 52 week high of $8.90. The company's 50-day moving average price is $7.14 and its two-hundred day moving average price is $6.56.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09). The firm had revenue of $15.01 million during the quarter, compared to analysts' expectations of $14.93 million. Journey Medical had a negative net margin of 15.49% and a negative return on equity of 48.69%.

Hedge Funds Weigh In On Journey Medical

Large investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. increased its holdings in Journey Medical by 3.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company's stock valued at $1,994,000 after buying an additional 9,938 shares during the last quarter. Citadel Advisors LLC purchased a new position in Journey Medical in the fourth quarter valued at $174,000. Tang Capital Management LLC purchased a new position in Journey Medical in the fourth quarter valued at $6,747,000. Dimensional Fund Advisors LP purchased a new position in Journey Medical in the fourth quarter valued at $80,000. Finally, Cetera Investment Advisers increased its holdings in Journey Medical by 21.8% in the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after buying an additional 2,478 shares during the last quarter. Hedge funds and other institutional investors own 7.25% of the company's stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.